Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema

Although most hereditary angioedema (HAE) attacks appear to occur spontaneously, they can be precipitated by emotional stressors or physical triggers, including invasive medical or dental procedures or other physical trauma.1,2 Short-term prophylaxis (STP) is appropriate for patients anticipating situations that might precipitate an HAE attack.1,3–6 HAE guidelines recommend that plasma-derived C1 inhibitor (C1-INH) (10–20 U/kg of Berinert [CSL Behring, King of Prussia, Pennsylvania] or 1,000 to 2,000 U of Cinryze [ViroPharma Biologics, Inc, Lexington, Massachusetts]), administered within 6 hours (within 24 hours for Cinryze) before the stressor event, be used as first-line treatment, if available, in situations in which STP is desired.

http://ift.tt/2f1YA3x